In this video, Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, talks about how novel immunotherapeutic options could reduce the high rate of refractory acute lymphoblastic leukemia (ALL) that has resulted from the use of multiple chemotherapeutic agents. Dr DeAngelo describes the aim to identify patients who are at high risk of relapse from standard therapy, and to incorporate immunotherapeutic options within their induction therapy. This video was recorded at the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal.
Immunotherapy for reducing the rate of relapsed/refractory ALL
